Stockscreener 앱 받기
33.41
11.00%
3.31
전일 마감가:
$30.10
열려 있는:
$30
하루 거래량:
1.21M
Relative Volume:
1.70
시가총액:
$1.83B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-15.56
EPS:
-2.1478
순현금흐름:
$-105.32M
1주 성능:
-2.22%
1개월 성능:
-15.22%
6개월 성능:
-8.16%
1년 성능:
-34.96%
1일 변동 폭
$29.60
$34.00
1주일 범위
$29.48
$34.00
52주 변동 폭
$26.61
$66.38
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(628) 229-9277
주소
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| GPCR | 33.41 | 1.83B | 0 | -100.44M | -105.32M | -2.1478 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital - Defense World
GPCRStructure Therapeutics Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.9%Here's What Happened - MarketBeat
Structure Therapeutics to Present at Jefferies London Healthcare Conference | GPCR Stock News - StockTitan
GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Reports Strong Q3 2024 Results - TipRanks
Structure Therapeutics Advances Obesity Drug Trial, Reports $915M Cash Position | GPCR Stock News - StockTitan
Structure Therapeutics Launches Phase 2b Obesity Drug Trial, Expands Testing to Higher Doses | GPCR Stock News - StockTitan
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Is Viking Therepautics a Buy Now? - MSN
Oral Proteins and Peptides Market to Reach $28.17 Billion by 2031 As Revealed In New Report - WhaTech
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - MedCity News
Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc - MarketBeat
Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register
Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Armata Pharmaceuticals Announces Structural Biology Publication - StockTitan
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat
GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive
Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Exchange Traded Concepts LLC Has $1.80 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR Inc. (GPCR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -1.39, Closing at 38.32 - The Dwinnex
Is Structure Therapeutics Inc ADR (GPCR) a threat to investors? - US Post News
Structure Therapeutics (NASDAQ:GPCR) Shares Down 2.7%Here's What Happened - MarketBeat
Structure Therapeutics Inc ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Top investors say Structure Therapeutics Inc ADR (GPCR) ticks everything they need - SETE News
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. - BioPharma Dive
Weight Loss Drugs Market Top Trends 2024-2031 - InsightAce Analytic
Market Recap Check: Structure Therapeutics Inc ADR (GPCR)’s Positive Finish at 40.50, Up/Down 0.30 - The Dwinnex
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7%Here's What Happened - MarketBeat
The Manufacturers Life Insurance Company Buys 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) is a good investment, but the stock may be overvalued - US Post News
27,094 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Bank of Montreal Can - MarketBeat
35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLC - Defense World
Marshall Wace LLP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
3 AI Stocks to Buy as Nvidia Sputters - InvestorPlace
Are Structure Therapeutics Inc ADR (GPCR) shares a good deal now? - US Post News
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - MarketBeat
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - BioSpace
Nasdaq Global Select Market Composite Index (NQGS) QuotePress Release - The Globe and Mail
S&P 100 Index (OEX) QuotePress Release - The Globe and Mail
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):